PD-(L)1 axis inhibits CAR-T cell activation, proliferation, survival, and functionality. Thus, CAR-T mediated direct targeting of the PD-(L)1 immunosuppressive axis or modulation of the axis along with CAR-T therapy holds a huge promise to unleash the full potential of CAR-Ts.
Multiple strategies are under investigation to target PD-(L)1 immunosuppressive axis to increase CAR-T therapy efficacy. We have grouped the strategies under the following three broad categories,
Combining CAR-Ts with PD-(L)1 inhibitors to target PD-(L)1 molecules
Engineering T-cells in CAR-Ts with molecular mechanisms to block PD-(L)1 axis
Modifying CARs to target the PD-(L)1 axis
Currently, 205+ CAR-T programs are investigating such strategies in clinical and preclinical studies. Some of these studies have shown promising efficacy and considerable safety profiles, thus providing a strong impetus for further progress along this path.
In this slide deck, the Oncofocus’ Cell and Gene therapy team provided a top-level summary of all the different strategies/sub-strategies employed to target the PD-(L)1 axis with CAR-Ts or along with CAR-Ts. To get a detailed report along with the list of all the 205+ programs, active developers, current status, clinical outcomes, etc., please write to us at email@example.com.
Please write to us at – firstname.lastname@example.org
To get a comprehensive analysis of each of these strategies and details of all the programs
To access clinical outcomes of all the programs evaluating these strategies
To understand other research strategies under investigation to improve the efficacy of CAR-Ts
To get complete access to the landscape of 3,000+ CAR-Ts and other cell and gene therapies